...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Est. Cash Position

It doesn't seem great! It seems like they needed money, haha! They originally gave up the patentsĀ  and would have received another $5 million milestone payment. Then they got the patents back by giving up that milestone payment. Now they give up the patents for $1.5 million loan. On the surface it looks like they got a lot less for the patents but there can be a lot under the surface that we don't know. The milestone payment maybe meant they had to proceed with a trial course that is longer the best route. You have to weigh it against newer trials that might be focused better and what partners are paying for in those. Too much unknown to make an informed comment.

Share
New Message
Please login to post a reply